Biogen Inc. Share Price

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 01:30:00 13/07/2024 am IST 5-day change 1st Jan Change
230.1 USD -2.85% Intraday chart for Biogen Inc. +1.95% -11.09%
Sales 2024 * 9.52B 795B Sales 2025 * 9.55B 798B Capitalization 33.5B 2,798B
Net income 2024 * 1.9B 159B Net income 2025 * 2.2B 184B EV / Sales 2024 * 3.84 x
Net Debt 2024 * 3.05B 255B Net Debt 2025 * 718M 59.98B EV / Sales 2025 * 3.58 x
P/E ratio 2024 *
18.1 x
P/E ratio 2025 *
15.6 x
Employees 7,570
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.85%
1 week+1.95%
Current month-0.76%
1 month-1.62%
3 months+16.09%
6 months-7.28%
Current year-11.09%
More quotes
1 week
225.59
Extreme 225.59
238.00
1 month
220.02
Extreme 220.02
238.00
Current year
189.44
Extreme 189.44
268.30
1 year
189.44
Extreme 189.44
281.12
3 years
187.16
Extreme 187.16
351.86
5 years
187.16
Extreme 187.16
468.55
10 years
187.16
Extreme 187.16
480.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 14/22/14
Director of Finance/CFO 60 15/20/15
Chief Operating Officer - 01/15/01
Members of the board TitleAgeSince
Director/Board Member 75 01/10/01
Director/Board Member 70 19/19/19
Chairman 64 03/10/03
More insiders
Date Price Change Volume
12/24/12 230.1 -2.85% 1,473,172
11/24/11 236.8 +1.74% 667,222
10/24/10 232.8 +1.61% 522,604
09/24/09 229.1 +0.43% 518,862
08/24/08 228.1 +1.07% 535,613

Delayed Quote Nasdaq, July 13, 2024 at 01:30 am IST

More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
230.1 USD
Average target price
281.3 USD
Spread / Average Target
+22.27%
Consensus